# Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

> **NCT02461992** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Intravenous infusions of Xyntha

## Key facts

- **NCT ID:** NCT02461992
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461992, "Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02461992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*